Logo image of RPTX

REPARE THERAPEUTICS INC (RPTX) Stock Fundamental Analysis

NASDAQ:RPTX - Nasdaq - US7602731025 - Common Stock - Currency: USD

1.52  +0.02 (+1.33%)

After market: 1.53 +0.01 (+0.66%)

Fundamental Rating

3

Overall RPTX gets a fundamental rating of 3 out of 10. We evaluated RPTX against 551 industry peers in the Biotechnology industry. While RPTX has a great health rating, there are worries on its profitability. RPTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RPTX has reported negative net income.
In the past year RPTX has reported a negative cash flow from operations.
In the past 5 years RPTX always reported negative net income.
In the past 5 years RPTX reported 4 times negative operating cash flow.
RPTX Yearly Net Income VS EBIT VS OCF VS FCFRPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -88.96%, RPTX is not doing good in the industry: 72.78% of the companies in the same industry are doing better.
With a Return On Equity value of -102.42%, RPTX perfoms like the industry average, outperforming 45.01% of the companies in the same industry.
Industry RankSector Rank
ROA -88.96%
ROE -102.42%
ROIC N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
RPTX Yearly ROA, ROE, ROICRPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

RPTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPTX Yearly Profit, Operating, Gross MarginsRPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

7

2. Health

2.1 Basic Checks

RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
RPTX has more shares outstanding than it did 1 year ago.
RPTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RPTX Yearly Shares OutstandingRPTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPTX Yearly Total Debt VS Total AssetsRPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

RPTX has an Altman-Z score of -4.29. This is a bad value and indicates that RPTX is not financially healthy and even has some risk of bankruptcy.
RPTX's Altman-Z score of -4.29 is in line compared to the rest of the industry. RPTX outperforms 43.56% of its industry peers.
RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.29
ROIC/WACCN/A
WACC9.93%
RPTX Yearly LT Debt VS Equity VS FCFRPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

RPTX has a Current Ratio of 7.42. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
RPTX has a better Current ratio (7.42) than 67.51% of its industry peers.
A Quick Ratio of 7.42 indicates that RPTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.42, RPTX is doing good in the industry, outperforming 68.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.42
RPTX Yearly Current Assets VS Current LiabilitesRPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

RPTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -166.36%.
The Revenue for RPTX has decreased by -98.90% in the past year. This is quite bad
The Revenue has been growing by 91.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-166.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-310%
Revenue 1Y (TTM)-98.9%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 16.74% on average over the next years. This is quite good.
RPTX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-7.58%
EPS Next 2Y10%
EPS Next 3Y-6.24%
EPS Next 5Y16.74%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RPTX Yearly Revenue VS EstimatesRPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2030 20M 40M 60M 80M 100M
RPTX Yearly EPS VS EstimatesRPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RPTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RPTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPTX Price Earnings VS Forward Price EarningsRPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPTX Per share dataRPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as RPTX's earnings are expected to decrease with -6.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10%
EPS Next 3Y-6.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RPTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REPARE THERAPEUTICS INC

NASDAQ:RPTX (8/4/2025, 7:24:11 PM)

After market: 1.53 +0.01 (+0.66%)

1.52

+0.02 (+1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners68.6%
Inst Owner Change-3.81%
Ins Owners0.38%
Ins Owner Change2.28%
Market Cap65.19M
Analysts78
Price Target6.63 (336.18%)
Short Float %1.44%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.24%
Min EPS beat(2)5.7%
Max EPS beat(2)16.77%
EPS beat(4)4
Avg EPS beat(4)9.69%
Min EPS beat(4)5.7%
Max EPS beat(4)16.77%
EPS beat(8)7
Avg EPS beat(8)230.14%
EPS beat(12)8
Avg EPS beat(12)176.84%
EPS beat(16)10
Avg EPS beat(16)131.54%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-91.01%
Min Revenue beat(4)-100%
Max Revenue beat(4)-64.03%
Revenue beat(8)2
Avg Revenue beat(8)-17.89%
Revenue beat(12)4
Avg Revenue beat(12)565.15%
Revenue beat(16)6
Avg Revenue beat(16)429.01%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.97%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.76
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-2.93
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0.03
BVpS2.92
TBVpS2.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -88.96%
ROE -102.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.42
Altman-Z -4.29
F-Score2
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)43.21%
Cap/Depr(5y)98.7%
Cap/Sales(3y)1.42%
Cap/Sales(5y)453.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-166.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-310%
EPS Next Y-7.58%
EPS Next 2Y10%
EPS Next 3Y-6.24%
EPS Next 5Y16.74%
Revenue 1Y (TTM)-98.9%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-85.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5635.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7953.29%
OCF growth 3YN/A
OCF growth 5YN/A